First-line therapy in ovarian cancer trials

Area of Science:

• Gynecology
• Oncology
• Clinical Trial Design

Background:

• The Gynecologic Cancer InterGroup (GCIG) convened its 4th Ovarian Cancer Consensus Conference in June 2010.
• Representatives from 23 international cooperative research groups participated.

Purpose of the Study:

• To establish international consensus on critical issues for conducting large randomized trials in ovarian cancer.
• To address key questions regarding first-line therapies for newly diagnosed ovarian cancer patients.

Main Methods:

• The conference focused on 13 predetermined questions.
• Discussion Group A addressed five questions related to first-line therapies, including trial endpoints, patient subgroups, comparator arms, chemotherapy modifications, and surgical roles.

Main Results:

• Consensus was sought on appropriate endpoints for various trial types (maintenance, upfront chemotherapy, molecular drugs).
• The need for specific treatment options and trials for subgroups defined by tumor biology was examined.
• The validity of the 2004 GCIG-recommended standard comparator arm was re-evaluated.
• The role of modifying chemotherapy dose, schedule, and delivery was discussed.
• The current role of surgery in ovarian cancer treatment was a key discussion point.

Conclusions:

• The conference aimed to provide guidance for future large-scale randomized trials in ovarian cancer.
• Establishing consensus on these critical issues is vital for advancing ovarian cancer research and treatment.
• The discussions inform the ongoing development of optimal treatment strategies and clinical trial designs for ovarian cancer.